Loading...
On November 22, 2013, the FDA approved the first adjuvanted H5N1 avian influenza vaccine for adults. The U.S. government has purchased it for inclusion in the national stockpile and, in the event of a pandemic, distribution by public health officials. The vaccine will not be available commercially. A non-adjuvanted vaccine from a different manufacturer, approved in 2007, is already in the national stockpile. Both vaccines use an egg-based manufacturing process.
The inclusion of an adjuvant in this new vaccine produces a stronger immune response while using less influenza antigen per dose, potentially making a higher number of doses available for use during a pandemic. This adjuvant, when used in a European seasonal influenza vaccine manufact…